Gapping down
In reaction to earnings/guidance:
- KC -5.6%
Other news:
- DWAC -22.3% (Truth Social did not get shareholder support from Digital World (DWAC) to extend SPAC deal)
- BBBY -15.9% (mourns the loss of CFO)
- ALVO -6.3% (Update on Initial AVT02 Biologics License Application; also downgraded to Sell from Buy at Citigroup)
- ZYME -4.9% (Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers)
- APGN -1.5% (New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022)
- CHD -1.4% (signed a definitive agreement to acquire the Hero Mighty Patch brand and other acne treatment products for $630 mln, consisting of cash and Church & Dwight restricted stock)
Analyst comments:
- CG -2.2% (downgraded to Underperform from Buy at BofA Securities)
- ARI -1.3% (downgraded to Underweight from Neutral at JP Morgan)
- CIEN -0.8% (downgraded to Neutral from Overweight at JP Morgan)
